

UNITED STATES DEPA MENT OF COMMERCE Patent and Trademark Mics Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER FILING DAT	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/484,337 06/07	790 PREUFR	M 6550 (G+1) final.
		DRAPER, G
	18N2/1002	ART UNIT PAPER NUMBER
DEBRA HICKEY LAW DEPI M S AB 30 AMGEN BOULDER INC 3200 WALNUI STREEL BOULDER CO 80301-		19:12' DATE MAILED:
This is a communication from the exam COMMISSIONER OF PATENTS AND	ner in charge of your application.	10/0296
This application has been examine A shortened statutory period for respon	Responsive to communication filed on the to this action is set to expire more response will cause the application to become at	nth(s), 30 days from the date of this letter.
Part I THE FOLLOWING ATTACHM 1. Notice of References Cited	ENT(S) ARE PART OF THIS ACTION:	Notice of Draftsman's Patent Drawing Review, PTO-948
Notice of Art Cited by Applic Information on How to Effect	ant, PTO-1449. 4.	Notice of Informal Patent Application, PTO-152.
Part II SUMMARY OF ACTION 1 Claims Of the above, claims		are pending in the application
_		have been cancelled.
3. Claims		are allowed.
4. Claims		are rejected.
5. Claims		are objected to.
Claims_/-2/_		are subject to restriction or election requirement.
7. This application has been filed	with informal drawings under 37 C.F.R. 1.85 wh	ich are acceptable for examination purposes.
8. Formal drawings are required	n response to this Office action.	
9. The corrected or substitute dra are acceptable; and acceptable.	wings have been received on eptable (see explanation or Notice of Draftsman's	. Under 37 C.F.R. 1.84 these drawings s Patent Drawing Review, PTO-948).
	bstitute sheet(s) of drawings, filed on the examiner (see explanation).	. has (have) been approved by the
11. The proposed drawing correct	on, filed, has been	approved; disapproved (see explanation).
12. Acknowledgement is made of been filed in parent applica	the claim for priority under 35 U.S.C. 119. The claim, serial no; filed on _	certified copy has
13. Since this application apppear accordance with the practice to	s to be in condition for allowance except for form nder Ex parte Quayle, 1935 C.D. 11; 453 O.G. 2	al matters, prosecution as to the merits is closed in 113.
14. Other		

Art Unit: 1811

1. A telephone call was made to Thomas Zindrick on 9-24-96 and 9-30-96 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicants have indicated that they are not able to elect by telephone at this time because of the uncertainty of which group to choose. This is because one of their other applications has gone abandoned and they are trying to revive. In that application claims to the protein were being examined. The outcome of whether this application will be revived will determine which group is elected herein. Base on the above, a written restriction is being issued in the interest of time.

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-11, drawn to a TNF inhibitor, classified in class 530, subclass 350.
 - II. Claims 12-21, drawn to a recombinant method of making a TNF inhibitor and the gene that encodes such, classified in classes 435 and 536, subclass 69.1 and 23.5 respectively

The inventions are distinct, each from the other because:

Inventions of Group I and Group II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the protein can be prepared by a materially different process such as by isolation from nature using various isolation/purification/chromatographic procedures; or the protein can be prepared by chemical synthesis. Furthermore, the products of these two group (e.g. the protein and the DNA) are physically, functionally and patentably distinct, and if determined to be patentable they would be patentably distinct. The DNA can also be used other than to make the protein of Group I such as it's use as a probe or in gene therapy.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, which are not co-extensive, thus restriction for examination purposes as indicated is proper

Serial Number: 08/484337 Page 3

Art Unit:

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

3. Any inquiry concerning this communication should be directed to Garnette D. Draper at

telephone number (703) 308-4232.

GARNETTE D. DRAPER PRIMARY EXAMINER

GROUP 1800